https://scholars.lib.ntu.edu.tw/handle/123456789/544151
標題: | Ketoconazole in Taiwanese castration-resistant prostate cancer patients: Evaluation of response rates, durations, and predictors | 作者: | Chiang B.-J. YEONG-SHIAU PU HONG-JENG YU CHAO-YUAN HUANG |
公開日期: | 2012 | 出版社: | Elsevier B.V. | 卷: | 23 | 期: | 2 | 起(迄)頁: | 48-51 | 來源出版物: | Urological Science | 摘要: | Background/purpose: To evaluate the efficacy of ketoconazole in castration-resistant prostate cancer. Materials and methods: We reviewed the medical records of consecutive patients with pathologically confirmed prostate cancer from May 2006 to December 2008. The inclusion criteria were: (1) receiving 200 or 400 mg ketoconazole three times daily and replacement doses of prednisolone; (2) antiandrogen withdrawal for at least 2 months before ketoconazole treatment; and (3) no prior cytotoxic agents or other CYP17 inhibitors. Treatment consisted of ketoconazole at 200 mg three times daily (Group A) and 400 mg three times daily (Group B). Patients' characteristics, time to prostate-specific antigen (PSA) progression, duration of PSA response, and adverse events were evaluated. Results: Of the 37 patients in Group A, 14 (37.8%) experienced a PSA response. Of the seven patients in Group B, four (57.1%) experienced a PSA response. Median durations of time to progression in those who experienced a > 50% PSA decline were 7.5 and 11.5 months in Group A and Group B, respectively. Median duration of PSA response was 5.5 and 9.0 months in Group A and Group B, respectively. There was no difference in the PSA response or time to progression between the two groups. Orchiectomy had a borderline unfavorable effect on the PSA response rate (. p = 0.067). Conclusion: The present study demonstrated that ketoconazole contributed to the PSA response in patients with castration-resistant prostate cancer. The efficacy and toxicity profiles were comparable to those in previous studies. Orchiectomy had a borderline unfavorable effect on PSA response rate. Further studies are required to confirm the efficacy of ketoconazole therapy in surgically castrated patients. ? 2012. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84862663070&doi=10.1016%2fj.urols.2012.04.004&partnerID=40&md5=b065e7b751f2369138077f6a14f3fedd https://scholars.lib.ntu.edu.tw/handle/123456789/544151 |
ISSN: | 1879-5226 | DOI: | 10.1016/j.urols.2012.04.004 | SDG/關鍵字: | ketoconazole; prostate specific antigen; adult; aged; article; cancer growth; castration resistant prostate cancer; clinical article; controlled study; dose response; drug dose comparison; drug efficacy; drug safety; epigastric pain; fatigue; headache; heart arrhythmia; human; liver function; male; medical record review; nausea; orchiectomy; priority journal; side effect; Taiwan; treatment duration; treatment outcome; vertigo |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。